← All trials
NCT06982521
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2025
- Primary completion
- Apr 30, 2028
- Completion date
- Dec 31, 2031
- First posted
- May 21, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Relay Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.